Every treatment has unintended adverse effects, and androgen deprivation therapy (ADT) for prostate cancer is no exception. A flurry of reports has implicated ADT in increasing cardiovascular risk and mortality. In this regard, the 2009 study by Efstathiou and colleagues is a notable exception.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Laaksonen, D. E. et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 27, 1036–1041 (2004).
Malkin, C. J. et al. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J. Clin. Endocrinol. Metab. 89, 3313–3318 (2004).
Laughlin, G. A., Barrett-Connor, E. & Bergstrom, J. Low serum testosterone and mortality in older men. J. Clin. Endocrinol. Metab. 93, 68–75 (2008).
Smith, J. C. et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J. Clin. Endocrinol. Metab. 86, 4261–4267 (2001).
Basaria, S., Muller, D. C., Carducci, M. A., Egan, J. & Dobs, A. S. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 106, 581–588 (2006).
Braga-Basaria, M. et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J. Clin. Oncol. 24, 3979–3983 (2006).
Keating, N. L., O'Malley, A. J. & Smith, M. R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J. Clin. Oncol. 24, 4448–4456 (2006).
D'Amico, A. V. et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J. Clin. Oncol. 25, 2420–2425 (2007).
Tsai, H. K., D'Amico, A. V., Sadetsky, N., Chen, M. H. & Carroll, P. R. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J. Natl Cancer Inst. 99, 1516–1524 (2007).
Efstathiou, J. A. et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85–31. J. Clin. Oncol. 27, 92–99 (2009).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Basaria, S. Cardiovascular mortality and androgen deprivation. Nat Rev Urol 6, 252–253 (2009). https://doi.org/10.1038/nrurol.2009.75
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2009.75
This article is cited by
-
Salvage cryotherapy with third-generation technology for locally recurrent prostate cancer after radiation therapy
International Urology and Nephrology (2016)